How to Get Mounjaro Without Insurance in 2026
Mounjaro's list price is $1,069 per month, and unlike its sister drug Zepbound, there is no LillyDirect self-pay vial program for Mounjaro. The realistic cash-pay paths bring it down to roughly $299–$499/month in May 2026. For most non-diabetic cash-pay patients, switching to Zepbound is the cheaper move.
The honest answer first: most cash-pay patients should switch to Zepbound
Mounjaro and Zepbound are the exact same molecule (tirzepatide). Mounjaro is the type 2 diabetes brand; Zepbound is the weight-loss brand. Eli Lilly only offers a self-pay vial program for Zepbound — starting around $349/month for the lower doses. If you do not have a type 2 diabetes diagnosis, almost no insurer will cover Mounjaro for you, and your cheapest path is Zepbound LillyDirect, not branded Mounjaro.
Read on if you specifically need Mounjaro (e.g. you have diabetes coverage), or skip ahead to How to Get Zepbound Without Insurance.
Cash-pay Mounjaro paths at a glance
| Path | Monthly | Annual |
|---|---|---|
| Mounjaro Savings Card (commercial insurance + diabetes Dx) | ~$25 | ~$300 |
| Switch to Zepbound LillyDirect vials (same molecule) | $349 | $4,188 |
| Compounded tirzepatide via telehealth | $299 | $3,588 |
| Branded Mounjaro via telehealth | $499 | $5,988 |
| Cash retail (full WAC) | $1,069 | $12,828 |
1. Mounjaro Savings Card (if you have commercial insurance + a T2D diagnosis)
If your commercial insurance covers Mounjaro for type 2 diabetes but the copay is high, the Eli Lilly Mounjaro Savings Card typically drops the copay to ~$25/month. Apply at mounjaro.lilly.com.
Government insurance — Medicare, Medicaid, Tricare, VA — is excluded by federal anti-kickback rules. If you have one of those plans, the savings card will not work regardless of your diagnosis.
See our full GLP-1 Savings Cards guide for both Mounjaro and Zepbound program details.
2. Switch to Zepbound LillyDirect vials ($349/mo)
Zepbound is the exact same molecule as Mounjaro — tirzepatide— just the weight-loss-indicated brand instead of the diabetes-indicated brand. Eli Lilly's LillyDirect program sells Zepbound vials at $349/month for the 2.5 mg and 5 mg starting doses, versus a Mounjaro WAC of $1,069.
This is the cheapest legitimate cash-pay path to tirzepatide in 2026 if you can use the Zepbound brand. The trade-off vs Mounjaro pens is a manual syringe draw with a vial. Higher doses (7.5+ mg) are not in the LillyDirect self-pay menu.
Visit LillyDirect →3. Compounded tirzepatide (~$299/mo, where available)
Compounded tirzepatide is a personalized formulation made by a US-licensed 503A compounding pharmacy. The FDA officially ended the tirzepatide shortage in late 2024, narrowing the regulatory shield, but some 503A pharmacies continue to produce case-by-case formulations through licensed telehealth.
As of May 2026, expect availability and pricing to vary by state and platform. Pricing is typically in the $299-per-month range. Avoid any "research-grade" or international peptide sources — those are not legal for human use and have unverified purity.
4. Branded Mounjaro via telehealth (~$499/mo)
If you specifically need branded Mounjaro (some patients prefer to keep the same brand their physician started them on), branded Mounjaro through telehealth typically runs around $499 per month, including the prescriber visit and shipment. This will require a clinically appropriate diagnosis on your chart.
Major telehealth options as of May 2026:
- Hims & Hers — fast onboarding, in-house pharmacy
- Ro — Body Program with coaching
- Lemonaid Health — pay per visit, not subscription
- LifeMD — wide GLP-1 menu
See our full telehealth provider comparison.
5. Run the comparison vs Zepbound and Wegovy
For most non-diabetic cash-pay patients, the right move is Zepbound LillyDirect, not branded Mounjaro. For patients who tolerate semaglutide better than tirzepatide, Wegovy NovoCare may also be in range. Run the math:
- Mounjaro vs Zepbound — same molecule, different cash-pay landscape
- How to Get Zepbound Without Insurance — full Zepbound playbook
- How to Get Wegovy Without Insurance — semaglutide alternative
- Cheapest GLP-1 finder — full ranking with $/lb breakdown
- Tirzepatide cost overview — molecule-level guide across all brands and channels
Frequently asked questions
How much does Mounjaro cost without insurance in 2026?
The list price (Wholesale Acquisition Cost) is $1,069 per 28-day supply, but almost no one pays that without coverage. The realistic cash-pay floor in May 2026 is roughly $299–$499 per month through telehealth platforms. Mounjaro itself does not have a LillyDirect self-pay vial program — that exists only for Zepbound.
Why is there no LillyDirect self-pay program for Mounjaro?
LillyDirect's self-pay vial program is structured around Zepbound (the weight-loss-indicated brand), not Mounjaro (the type 2 diabetes brand), even though they are the same molecule (tirzepatide). For cash-pay patients without diabetes coverage, the Zepbound LillyDirect vial path is almost always the cheaper way to get tirzepatide — it starts around $349/month for the 2.5 mg and 5 mg starting doses.
Is the Mounjaro Savings Card the same as LillyDirect?
No — they are two different programs. The Mounjaro Savings Card (mounjaro.lilly.com) reduces the copay (often to ~$25/month) for patients whose commercial insurance already covers Mounjaro for type 2 diabetes. LillyDirect is a separate self-pay storefront and only covers Zepbound, not Mounjaro. Government insurance (Medicare, Medicaid, Tricare, VA) is excluded from the savings card by federal anti-kickback rules.
Should I switch from Mounjaro to Zepbound to save money?
If you do not have type 2 diabetes, almost certainly yes. Zepbound is the same molecule (tirzepatide) approved for chronic weight management, and Eli Lilly's LillyDirect self-pay vials start around $349/month for the 2.5 mg and 5 mg starting doses — there is no equivalent program for Mounjaro. If you do have type 2 diabetes and your insurance covers Mounjaro but not Zepbound, the diabetes-channel copay is usually still the cheapest path.
Is compounded tirzepatide still available in 2026?
Yes, but availability narrowed sharply after the FDA officially ended the tirzepatide drug shortage in late 2024. Some 503A pharmacies still produce personalized formulations on a case-by-case basis through licensed telehealth, but legal posture varies by state. Only use US-licensed, PCAB-accredited 503A pharmacies; avoid international "research peptide" sources, which are not legal for human use.
Will my insurance cover Mounjaro for off-label weight loss?
Almost never. Mounjaro's FDA-approved indication is type 2 diabetes. If you do not have a diabetes diagnosis (or the related ICD-10 code on your chart), commercial and government insurers will deny coverage. The pathway to insurance-covered tirzepatide for weight loss is Zepbound, not Mounjaro — and even Zepbound coverage is plan-dependent and often requires prior authorization.
Can I use a GoodRx coupon for Mounjaro?
Coupons rarely beat telehealth pricing for Mounjaro. Like Zepbound and Wegovy, Mounjaro is brand-name and patent-protected, so retail pharmacy cash prices stay close to the WAC even with coupons. GoodRx Care's telehealth option ($39/month) plus pharmacy cost is occasionally competitive but for most cash-pay patients, branded telehealth or — better — switching to Zepbound LillyDirect is the cheaper path.
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.